Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

RedChip will air sponsored interviews with Nova Minerals and FibroBiologics on Bloomberg TV and CNBC on September 26-27. Nova highlighted its fully funded $43.4 million U.S. Department of War-supported antimony program, targeting military-grade antimony trisulfide production in 2027, alongside a 5.2-million-ounce gold resource in Alaska. FibroBiologics highlighted expected 2026 data from its Phase 1/2 diabetic foot-ulcer study and an FDA-reviewed psoriasis IND, but the release is promotional content from a compensated investor-relations provider rather than a material operating update.

Analysis

This is paid investor-relations distribution rather than an independent operating catalyst, so any near-term reaction in FBLG should be treated as retail-flow volatility, not a change in probability-adjusted asset value. The relevant 1-3 month repricing event is clinical data: a clean, clinically meaningful diabetic-foot-ulcer signal could validate manufacturing consistency and biological activity, but a small early-stage study will not by itself establish broad platform economics. Cell-therapy peers typically face sharp multiple compression if efficacy lacks durability or if CMC/scalability costs emerge after initial proof of concept.

NVA is not in the supplied ticker set, but its strategic-minerals framing is directionally supportive for U.S.-exposed antimony optionality. The more investable second-order read-through is limited: credible domestic supply could ultimately pressure incumbents dependent on Chinese refined-antimony supply, while defense procurement could lower project-finance risk for U.S. miners. However, 2027 production targets remain execution-sensitive to permitting, recovery rates, refining qualification and capex; a grant reduces development funding risk but does not demonstrate commercial throughput or margins.

Contrarian view: sponsored television reach is often confused with institutional demand. For thinly traded microcaps, attention can temporarily widen volume and price dislocations, but it can also create a liquidity window for holders; absent filing-backed cash runway, trial design details, and independently verifiable milestones, there is no basis to underwrite a sustained rerating. The correct posture is event-driven monitoring rather than chasing a promotional move.

Key Decisions for Investors

• FBLG: do not initiate on broadcast-related strength; monitor the next 1-3 trading days for volume exceeding 5x its 20-day average without a contemporaneous SEC filing, and fade only if borrow is available and liquidity supports execution. Cover on a disclosed clinical-data date or material partnership, as either can overwhelm a technical mean-reversion thesis.
• FBLG watch item for 1-3 months: require disclosure of diabetic-foot-ulcer enrollment, endpoint definitions, follow-up durability, adverse events, manufacturing release specifications and cash runway before considering a long. A positive signal should be defined by clinically meaningful wound-closure separation with acceptable safety, not management commentary.
• NVA: no recommended position from this item. Reassess only after independently documented pilot recovery/yield, offtake or procurement terms, permitting progress, and a capex-to-first-production schedule; failure to meet any 2027 intermediate milestone would materially impair the critical-minerals premium.
• Avoid extrapolating this event to AAPL, CELH, CDTX, SBUX, NKE, WGO, DAKT, or K; their inclusion reflects the promoter's historical references rather than a financial linkage or read-through.